Boehringer-Ingelheim establishes D.C. presence
Executive Summary
Former American Hospital Association VP-Legislative Affairs Kirsten Morris and former Generic Pharmaceutical Association VP-Government Affairs Buddy Menn are establishing a Washington, D.C. office for Boehringer-Ingelheim. Menn was most recently chief-of-staff to Sen. Robert Graham (R-Fla.), and previously worked in government affairs for the National Association of Chain Drug Stores (1"The Pink Sheet" March 19, 2001, p. 7). The office opened in January. BI has a rapidly growing presence in the U.S. pharma market; its product line includes brands (Spiriva, Mobic, Aggrenox, Flomax, etc.), generics (Roxane labs), OTCs (Ducolax) and animal health...
You may also be interested in...
GPhA Lobbying Will Be Led By CEO Nixon Following Departure Of VP Menn
The Generic Pharmaceutical Association's lobbying efforts will be headed by CEO Bill Nixon following the departure of VP-Government Affairs Buddy Menn.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.